Anjan Patel, MD
Medical Oncology · Sarasota, FLNPI 1134388689
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Boehringer Ingelheim at 35.3% of the total.
Across 164 payments — averaging $80.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$5K
- Janssen Global Services, LLC$2K
- Taiho Oncology, Inc.$2K
- AstraZeneca$609
- Pfizer$499
- Johnson & Johnson$419
- plus $3K from 41 others
Across 360 payments — averaging $8290.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.7M
- Ipsen Bioscience Inc.$375K
- Genentech, Inc.$361K
- Mirati Therapeutics, Inc.$196K
- G1 Therapeutics, Inc.$133K
- Biontech SE$113K
- plus $137K from 5 others
What the payments were for
- Consulting fees$3,63027%
- Speaking & faculty fees$5,15839%
- Food & beverage$4,42833%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,270 in reported general payments places this provider in the 60th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 42 | $651,640 |
| PomalystPomalidomide | 27 | $562,749 |
| XtandiEnzalutamide | 32 | $431,767 |
| CabometyxCabozantinib S-Malate | 24 | $425,459 |
| OjjaaraMomelotinib Dihydrochloride | 14 | $399,531 |
| JakafiRuxolitinib Phosphate | 22 | $372,876 |
| AlecensaAlectinib Hcl | 21 | $367,991 |
| BrukinsaZanubrutinib | 17 | $253,832 |
| TasignaNilotinib Hcl | 12 | $241,710 |
| NubeqaDarolutamide | 20 | $214,339 |
| BosulifBosutinib | 11 | $195,221 |
| IbrancePalbociclib | 12 | $192,757 |
| ErleadaApalutamide | 12 | $174,677 |
| EliquisApixaban | 190 | $145,538 |
| CreonLipase/Protease/Amylase | 15 | $34,115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $83 | $651,64042 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $180 | $562,74927 claims |
| PfizerBosulif, Ibrance, Eliquis | $499 | $533,515213 claims |
| Astellas Pharma US IncXtandi | $172 | $431,76732 claims |
| GSKOjjaara | $109 | $399,53114 claims |
| Incyte CorporationJakafi | $55 | $372,87622 claims |
| NovartisTasigna | $185 | $241,71012 claims |
| BayerNubeqa | $155 | $214,33920 claims |
| Johnson & JohnsonErleada, Xarelto | $419 | $197,31945 claims |
| AbbVieCreon | $91 | $34,11515 claims |
| Lilly USA, LLCOlanzapine | $35 | $81833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Sarasota
- Manish PatelSarasota$123K
- Judy WangSarasota$64K
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.